Annual report pursuant to Section 13 and 15(d)

Segment Reporting

v3.22.0.1
Segment Reporting
 12 Months Ended
Nov. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting

NOTE 5 – SEGMENT REPORTING

The Company is organized in three reportable segments:

1.
The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. Revenue is generated from the initial processing and testing fees and the annual storage fees charged each year for storage (the “Umbilical cord blood and cord tissue stem cell service”).
2.
The manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. Revenue is generated from the sales of the PrepaCyte CB units (the “PrepaCyte CB”).
3.
The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. Revenue is generated from the sale of the cord blood units to the National Marrow Donor Program (“NMDP”), which distributes the cord blood units to transplant centers located in the United States, and around the world.

The following table shows, by segment: net revenue, cost of sales, operating profit, depreciation and amortization, interest expense, and assets for the years ended November 30, 2021 and November 30, 2020:

 

 

 

For the years ended November 30,

 

 

 

2021

 

 

2020

 

Net revenue:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

28,397,401

 

 

$

30,176,852

 

PrepaCyte CB

 

 

111,400

 

 

 

244,187

 

Public cord blood banking

 

 

376,101

 

 

 

726,554

 

Total net revenue

 

$

28,884,902

 

 

$

31,147,593

 

Cost of sales:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

7,351,410

 

 

$

7,689,608

 

PrepaCyte CB

 

 

154,140

 

 

 

156,111

 

Public cord blood banking

 

 

1,484,186

 

 

 

1,811,723

 

Total cost of sales

 

$

8,989,736

 

 

$

9,657,442

 

Operating profit:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

6,347,061

 

 

$

9,928,886

 

PrepaCyte CB

 

 

(70,335

)

 

 

60,499

 

Public cord blood banking

 

 

(2,273,604

)

 

 

(2,327,788

)

Total operating profit

 

$

4,003,122

 

 

$

7,661,597

 

Depreciation and amortization:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

806,230

 

 

$

138,859

 

PrepaCyte CB

 

 

27,595

 

 

 

27,578

 

Public cord blood banking

 

 

1,020

 

 

 

-

 

Total depreciation and amortization

 

$

834,845

 

 

$

166,437

 

Interest expense:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell service

 

$

1,378,926

 

 

$

1,544,017

 

PrepaCyte CB

 

 

-

 

 

 

-

 

Public cord blood banking

 

 

-

 

 

 

-

 

Total interest expense

 

$

1,378,926

 

 

$

1,544,017

 

 

The following table shows the assets by segment as of November 30, 2021 and November 30, 2020:

 

 

 

2021

 

 

2020

 

Assets:

 

 

 

 

 

 

Umbilical cord blood and cord tissue stem cell
   service

 

$

50,170,887

 

 

$

34,215,780

 

PrepaCyte CB

 

 

250,591

 

 

 

302,683

 

Public cord blood banking

 

 

10,240,598

 

 

 

11,681,631

 

Total assets

 

$

60,662,076

 

 

$

46,200,094